Table 3.
Best response rates and overall survival (OS) between ccRCC and nccRCC
| General Comparison | nccRCC Subtypes Compared to ccRCC | |||||
|---|---|---|---|---|---|---|
| ccRCC | nccRCC | pRCC | chRCC | unRCC | Other/Unknown | |
|
BR 1-st line
CR/PR/SD/PD (%) |
17 / 428 / 803 / 350 (1.1 / 26.8 / 50.2 / 21.9) |
2 / 30 / 101 / 69 (1.0 / 14.9 / 50.0 / 34.2) |
0 / 17 / 63 /41 (0 / 14.0 / 52.1 / 33.9) |
1 / 6 / 16 / 9 (3.1 / 18.8 / 50.0 / 28.1) |
1 / 6 / 9 / 9 (4.0 / 24.0 / 36.0 / 36.0) |
0 / 1 / 13 / 10 (0/4.2 / 54.2 / 41.7) |
|
BR 2-nd line
CR/PR/SD/PD (%) |
3 / 76 / 334 / 261 (0.4 / 11.3 / 49.6 / 38.7) |
0 / 7 / 37 / 38 (0 / 8.5 / 45.1 / 46.3) |
0 / 2 / 22 / 20 (0 / 4.5 / 50.0 / 45.5) |
0 / 2 / 5 / 7 (0 / 14.3 / 35.7 / 50.0) |
0 / 1 / 4 / 5 (0 / 10 / 40 / 50) |
0 / 2 / 6 / 6 (0 / 14.3 / 42.9 / 42.9) |
|
OS analyses
N |
1963 | 252 | 151 | 37 | 34 | 30 |
| No. deaths | 1240 | 177 | 105 | 21 | 24 | 27 |
|
Median
(95% CI) |
22.3 (20.7,23.5) |
12.8 (11.0,16.1) |
14.0 (10.9,17.1) |
27.1 (12.6,75.3) |
10.1 (5.1,13.2) |
11.3 (9.6,19.4) |
|
Unadjusted
HR (95% CI) |
reference | 1.44 (1.23,1.69) |
1.48 (1.21,1.81) |
0.98 (0.64,1.51) |
1.71 (1.14,2.56) |
1.67 (1.14,2.45) |
|
Unadjusted
p-value |
<0.0001 | 0.0001 | 0.923 | 0.010 | 0.008 | |
|
Adjusted HR*
(95% CI) |
reference | 1.41 (1.19, 1.67) |
1.57 (1.27,1.94) |
0.89 (0.55,1.45) |
1.51 (0.98,2.31) |
1.30 (0.84,2.00) |
|
Adjusted
p-value * |
<0.0001 | <0.0001 | 0.646 | 0.060 | 0.243 | |
Abbreviations: ccRCC= clear cell renal cell carcinoma, nccRCC= non clear cell renal cell carcinoma, HR= hazard ratio; BR=best response
*
adjusted for the IMDC risk group criteria (time from diagnosis to treatment, Karnofsky performance status <80, hemoglobin <upper limit of normal, neutrophilia, thrombocytosis, hypercalcemia)